Premium
Quetiapine XR ‐induced neutropenia: is a clozapine trial still possible for treatment‐resistant schizophrenia? A case report
Author(s) -
CrépeauGendron Gabrielle,
L'Heureux Sophie
Publication year - 2015
Publication title -
early intervention in psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.087
H-Index - 45
eISSN - 1751-7893
pISSN - 1751-7885
DOI - 10.1111/eip.12134
Subject(s) - quetiapine , clozapine , neutropenia , medicine , schizophrenia (object oriented programming) , psychiatry , refractory (planetary science) , psychosis , absolute neutrophil count , pediatrics , chemotherapy , physics , astrobiology
Aim Our case report addresses the use of clozapine in patients who have a history of quetiapine XR‐induced neutropenia. There are no current guidelines for this situation. Methods We present the case of a young woman treated with clozapine at a first‐episode psychosis clinic after a moderate quetiapine XR ‐induced neutropenia (0,5–1,0 × 10 9 L −1 ). Results The patient was successfully treated with clozapine and lithium, with less psychotic symptoms and a better level of functioning. The neutrophil count remained normal during the treatment period, which has been longer than a year. Conclusion The outcome of this case supports the notion that clinicians could consider introducing clozapine in treatment‐refractory patients who have a history of quetiapine XR ‐induced neutropenia, with close blood monitoring. Lithium co‐administration may play a role in maintaining a normal neutrophil count.